Opinion
Video
Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma